(Reuters) – The U.S. Food and Drug Administration granted traditional approval for Pfizer’s drug for cervical cancer patients with disease progression on or after chemotherapy, the agency said on Monday.
(Reporting by Pratik Jain in Bengaluru; Editing by Anil D’Silva)
Comments